To date, ETI therapy demonstrated the best clinical efficacy in rescuing F508del-CFTR protein, allowing to target CF sub-populations, namely those carrying two copies of F508del-CFTR or those heterozygous for F508del-CFTR and a gating, residual, or MF CFTR mutation on the second allele. Here, CFTR is linked to cystic fibrosis.